Diabetes Autoantibody Testing and Management

Introduction to Autoantibody Testing

The American Diabetes Association recommends standardized islet autoantibody testing (GADA, IA-2A, ZnT8A, and IAA) for classification of diabetes in adults with phenotypic overlap between type 1 and type 2 diabetes, but not for routine diagnosis of diabetes in straightforward cases 1, 2
Glutamic Acid Decarboxylase Autoantibodies (GADA) are present in 70-80% of newly diagnosed T1DM patients and should be tested first as the primary marker 1, 3

Insulinoma-Associated Antigen-2 Autoantibodies (IA-2A) are detected in 50-60% of T1DM patients and indicate rapid progression risk 4
Zinc Transporter 8 Autoantibodies (ZnT8A) are found in approximately 50% of patients and serve as a surrogate marker of β-cell destruction 1
Insulin Autoantibodies (IAA) are present in 30-40% of T1DM patients, particularly in children, but only valid before insulin therapy begins 1, 4

A single persistent autoantibody is associated with a 15% risk of diabetes within 10 years 1, 6
Two or more autoantibodies are associated with a 70% risk of diabetes within 10 years, with 44% risk at 5 years for stage 1 disease 1, 6
Multiple autoantibodies with dysglycemia (stage 2) are associated with a 60% risk by 2 years and 75% within 5 years 3

The American Diabetes Association recommends a three-stage classification system for diabetes based on autoantibody testing: Stage 1 (normoglycemia), Stage 2 (dysglycemia), and Stage 3 (overt diabetes) 1, 2

The testing algorithm should start with GADA as the first-line test, followed by IA-2A and ZnT8A testing if GADA is negative 3, 5
IAA testing should be considered before insulin therapy begins 4, 5

Patients with multiple autoantibodies should be referred to specialized centers for evaluation and potential clinical trials, including consideration of teplizumab to delay disease progression 4
GADA-positive adults with diabetes phenotype should be recognized as having latent autoimmune diabetes in adults (LADA) and expect faster progression to absolute insulinopenia 3, 5
Patients with T1DM should be screened for associated autoimmune conditions, such as celiac disease and thyroid disease 3